Enliven Therapeutics, Inc. (ELVN) Misses Q1 EPS by 23c

Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported Q1 EPS of ($0.80), $0.23 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Enliven Therapeutics, Inc. (ELVN) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Ethos Technologies (LIFE) PT Raised to $38 at BofA Securities
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance